GLP-1 Peptide Atlas, by Delfa

Active not recruitingPhase 4

Use of Liraglutide in Children Aged 6 to 12 Years With Severe Obesity

Efficacy, Metabolic and Cardiovascular Effects of Liraglutide in Children Aged 6-12 Years With Severe Obesity: A Randomized Controlled Trial With Advanced Echocardiographic Assessment

Lead sponsor

University of Sao Paulo General Hospital

Asset

Liraglutide

Subcutaneous · GLP-1 agonist

Listed sites

Recruiting sites

—

Enrollment

estimated

Study population

Obesity / overweight

Key I/E criterion

•Age 6-12

Primary endpoint

•BMI, change

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT07590219

Org study ID74225723.4.0000.0068

Timeline

Milestones

Study start2024-03-30actual

Study first posted2026-05-15actual

Last update posted2026-05-15actual

Primary completion2027-04estimated (month precision)

Study completion2028-04estimated (month precision)

Assets

Investigational agents

Liraglutide

Study populations

Who this study enrolls

Obesity / overweight

Eligibility

Who can enroll

Minimum age6 Years

Maximum age12 Years

SexAll

Healthy volunteersNot accepted

Inclusion criteria

•Children aged 6-12 years

•BMI Z-score ≥ +3

•Previous unsuccessful lifestyle intervention

Exclusion criteria

•Severe chronic diseases

•Cardiac disease

•Dermatological contraindication

•Use of interfering medications

Endpoints (9)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Cardiometabolic biomarkers

Glycemic / diabetes

Other (unclassified)

Weight & body composition

1 endpoint

Primary/protocol endpoint

Change in Body Mass Index (BMI)

Time frame:6 months

BMI, change

change from baseline, improvement

Glycemic / diabetes

2 endpoints

Secondary/protocol endpoint

Change in fasting plasma glucose

Time frame:Baseline to 6 months

Fasting glucose, change

change from baseline, improvement

LOINC 1558-6

Secondary/protocol endpoint

Change in fasting insulin levels

Time frame:6 months

change from baseline, improvement

Cardiometabolic biomarkers

4 endpoints

Secondary/protocol endpoint

Change in triglyceride levels

Time frame:6 months

Triglycerides, change

change from baseline, improvement

LOINC 2571-8

Secondary/protocol endpoint

Change in total cholesterol levels

Time frame:6 months

Total cholesterol, change

change from baseline, improvement

LOINC 2093-3

Secondary/protocol endpoint

Change in HDL cholesterol levels

Time frame:6 months

HDL-C, change

change from baseline, improvement

LOINC 2085-9

Secondary/protocol endpoint

Change in LDL cholesterol levels

Time frame:6 months

LDL-C, change

change from baseline, improvement

LOINC 13457-7

Other (unclassified)

2 endpoints

Secondary/protocol endpoint/low confidence

Change in left ventricular global longitudinal strain (LV-GLS) measured by two-dimensional speckle-tracking echocardiography

Time frame:6 months

change from baseline, improvement

Secondary/protocol endpoint/low confidence

Change in left atrial reservoir strain (LASr) measured by two-dimensional speckle-tracking echocardiography

Time frame:6 months

change from baseline, improvement

Publications (12)

Bibliography

Records linked to this trial through ClinicalTrials.gov references, PubMed NCT search, and curated study seeds. 'Canonical' marks design/result papers; others are registry references or candidates.

Registry references + supporting bibliography

Determinants of obesity in Latin America.
Nature metabolism2024 Mar (month)PMID38438626doi:10.1038/s42255-024-00977-1via CT.gov background
Once-Weekly Semaglutide in Adolescents with Obesity.
The New England journal of medicine2022 Dec 15PMID36322838doi:10.1056/NEJMoa2208601via CT.gov background
A Randomized, Controlled Trial of Liraglutide for Adolescents with Obesity.
The New England journal of medicine2020 May 28PMID32233338doi:10.1056/NEJMoa1916038via CT.gov background
The Association of Matrix Metalloproteinases with Chronic Kidney Disease and Peripheral Vascular Disease: A Light at the End of the Tunnel?
Biomolecules2020 Jan 17PMID31963569doi:10.3390/biom10010154via CT.gov background
[Malignant conjunctival melanoma arising from conjunctival melanosis of Reese].
Journal francais d'ophtalmologie2017 Nov (month)PMID29055731doi:10.1016/j.jfo.2017.01.020via CT.gov background
Pediatric Obesity-Assessment, Treatment, and Prevention: An Endocrine Society Clinical Practice Guideline.
The Journal of clinical endocrinology and metabolism2017 Mar 1PMID28359099doi:10.1210/jc.2016-2573via CT.gov background
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.
The New England journal of medicine2016 Jul 28PMID27295427doi:10.1056/NEJMoa1603827via CT.gov background
[Clinical and pathological features of Denys-Drash syndrome: report of 3 cases].
Zhonghua er ke za zhi = Chinese journal of pediatrics2012 Nov (month)PMID23302619via CT.gov background
Prevalence of Otitis Media with Effusion among Primary School Children in Eastern Black Sea, in Turkey and the Effect of Smoking in the Development of Otitis Media with Effusion.
Indian journal of otolaryngology and head and neck surgery : official publication of the Association of Otolaryngologists of India2012 Mar (month)PMID23449553doi:10.1007/s12070-011-0131-zvia CT.gov background
Incretin-based therapies: viewpoints on the way to consensus.
Diabetes care2009 Nov (month)PMID19875556doi:10.2337/dc09-S315via CT.gov background
Association between multiple cardiovascular risk factors and atherosclerosis in children and young adults. The Bogalusa Heart Study.
The New England journal of medicine1998 Jun 4PMID9614255doi:10.1056/NEJM199806043382302via CT.gov background
The use of cohort vs repeated cross-sectional sample survey data in monitoring changing breast cancer screening practices.
Preventive medicine1995 Nov (month)PMID8610077doi:10.1006/pmed.1995.1088via CT.gov background

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 1, 2026

Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)

Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.